NASDAQ:SKYE Skye Bioscience (SKYE) Stock Price, News & Analysis → Gold Mania (From Stansberry Research) (Ad) Free SKYE Stock Alerts $13.02 +0.03 (+0.23%) (As of 05/3/2024 08:53 PM ET) Add Compare Share Share Today's Range$12.89▼$13.1050-Day Range$9.17▼$17.3652-Week Range$1.44▼$19.41Volume34,800 shsAverage Volume65,997 shsMarket Capitalization$160.80 millionP/E RatioN/ADividend YieldN/APrice Target$22.50 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesSEC FilingsShort InterestSocial Media Get Skye Bioscience alerts: Email Address Skye Bioscience MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside72.8% Upside$22.50 Price TargetShort InterestHealthy0.29% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.04Based on 3 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($0.79) to ($0.88) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.13 out of 5 starsMedical Sector4513th out of 5,424 stocksPharmaceutical Preparations Industry2113th out of 2,550 stocks 3.5 Analyst's Opinion Consensus RatingSkye Bioscience has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageSkye Bioscience has only been the subject of 2 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted0.29% of the outstanding shares of Skye Bioscience have been sold short.Short Interest Ratio / Days to CoverSkye Bioscience has a short interest ratio ("days to cover") of 1.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Skye Bioscience has recently increased by 5.23%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldSkye Bioscience does not currently pay a dividend.Dividend GrowthSkye Bioscience does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for SKYE. Previous Next 1.7 News and Social Media Coverage News SentimentSkye Bioscience has a news sentiment score of 0.04. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.42 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Skye Bioscience this week, compared to 0 articles on an average week.Search InterestOnly 2 people have searched for SKYE on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Skye Bioscience to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Skye Bioscience insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 0.73% of the stock of Skye Bioscience is held by insiders.Percentage Held by InstitutionsOnly 21.09% of the stock of Skye Bioscience is held by institutions. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Skye Bioscience are expected to decrease in the coming year, from ($0.79) to ($0.88) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Skye Bioscience is -1.22, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Skye Bioscience is -1.22, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Colonial MetalsThe Gold Grab of the CenturyWhen central banks buy gold… The rich buy right along with them. And central banks are buying at breakneck pace. Last year… 1,037 tons. Just 45 tons less than the record set two years ago.That's why we have released our Free Precious Metals Investment Guide. About Skye Bioscience Stock (NASDAQ:SKYE)Skye Bioscience, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes cannabinoid-based molecules for the treatment of infectious diseases. The company's lead product candidate is SBI-100 used in the treatment of glaucoma and ocular hypertension. It is also developing SBI-200 to treat and manage various eye diseases, including uveitis, dry eye syndrome, macular degeneration and diabetic retinopathy. It has license agreement with university of Mississippi. The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in January 2021. The company is headquartered in San Diego, California.Read More SKYE Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart SKYE Stock News HeadlinesMay 4, 2024 | americanbankingnews.comContrasting Skye Bioscience (SKYE) and Its RivalsMay 3, 2024 | americanbankingnews.comAnalyzing Skye Bioscience (SKYE) & Its CompetitorsMay 4, 2024 | Weiss Ratings (Ad)FW: 234x GainThis coin is an essential building block for an ongoing financial revolution of massive dimensions. As a big part of this revolution, the big banks of the world must connect to the blockchain.April 30, 2024 | globenewswire.comSkye Bioscience to Present Two Posters at Association for Research in Vision and Ophthalmology (ARVO) 2024 Annual MeetingApril 23, 2024 | globenewswire.comSkye Bioscience to Present at Upcoming Investment ConferencesApril 19, 2024 | investorplace.comThese 3 Small-Cap Stocks Are Up 304% in 2024. Can They Run Higher?April 18, 2024 | morningstar.comSkye Bioscience Inc Ordinary SharesApril 16, 2024 | investorplace.comThese 3 Biotech Stocks Are Up 269% in 2024. Is There More to Come?May 4, 2024 | Weiss Ratings (Ad)FW: 234x GainThis coin is an essential building block for an ongoing financial revolution of massive dimensions. As a big part of this revolution, the big banks of the world must connect to the blockchain.April 10, 2024 | finanznachrichten.deSkye Bioscience, Inc.: Skye Bioscience Uplists to The Nasdaq Global MarketApril 10, 2024 | globenewswire.comSkye Bioscience Uplists to The Nasdaq Global MarketMarch 15, 2024 | msn.comMercedes Mone Drops Julia Hart, Willow Nightingale Gets Main Event Win On AEW DynamiteMarch 14, 2024 | markets.businessinsider.comAnalysts’ Opinions Are Mixed on These Healthcare Stocks: Guardant Health (GH), Cue Health (HLTH) and Skye Bioscience (OtherSKYE)March 13, 2024 | finanznachrichten.deSkye Bioscience, Inc.: Skye Bioscience Announces $40 Million Private Placement Equity FinancingMarch 8, 2024 | investorplace.comAll Three of Our Analysts AgreeMarch 4, 2024 | globenewswire.comSkye Bioscience Appoints Dr. Annalisa Jenkins to Board of DirectorsFebruary 26, 2024 | globenewswire.comSkye Bioscience Completes Enrollment of Phase 2a Clinical Trial of SBI-100 Ophthalmic Emulsion in Glaucoma and Ocular HypertensionFebruary 7, 2024 | finance.yahoo.comSkye Bioscience to Present at Oppenheimer Investor ConferenceFebruary 6, 2024 | markets.businessinsider.comBuy Rating Affirmed for Skye Bioscience on Strong Drug Pipeline and Financial HealthJanuary 30, 2024 | msn.comSkye Bioscience Announces Private Placement DetailsJanuary 30, 2024 | msn.comSkye Bioscience Strikes Deal for $50M Capital BoostJanuary 29, 2024 | msn.comSkye Bioscience announces $50M private placementJanuary 29, 2024 | finance.yahoo.comSkye Bioscience Announces $50.25 Million Private Placement Equity FinancingDecember 11, 2023 | msn.comGlobal Cannabis Odyssey: Ontario Expansion, Australian Exports And Innovations In AfricaDecember 11, 2023 | finance.yahoo.comSkye Announces Clinical Development Plan in Obesity for Differentiated Peripheral CB1 Inhibitor, NimacimabDecember 5, 2023 | finance.yahoo.comSkye Bioscience and Tautomer Bioscience Enter Exclusive License for SBI-100 for Development and Sale of Products for Chronic Pain and Other Indications in South Africa and Rest of AfricaNovember 21, 2023 | finance.yahoo.comSkye Bioscience to Present at BTIG Ophthalmology Day and OIS XIII Ophthalmology Innovation SummitSee More Headlines Receive SKYE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Skye Bioscience and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today5/04/2024Next Earnings (Estimated)5/09/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:SKYE CUSIPN/A CIK1516551 Webskyebioscience.com Phone858-410-0266FaxN/AEmployees11Year FoundedN/APrice Target and Rating Average Stock Price Target$22.50 High Stock Price Target$25.00 Low Stock Price Target$20.00 Potential Upside/Downside+72.8%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($10.67) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-37,650,000.00 Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-438.15% Debt Debt-to-Equity RatioN/A Current Ratio0.84 Quick Ratio0.84 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($0.17) per share Price / Book-76.59Miscellaneous Outstanding Shares12,350,000Free Float12,259,000Market Cap$160.80 million OptionableN/A Beta1.74 Elon Musk's Next MoveWondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.Get This Free Report Key ExecutivesMr. Punit S. Dhillon B.A. (Age 44)Executive Chairman, President, CEO & Secretary Comp: $720kDr. Christopher G. Twitty Ph.D. (Age 51)Chief Scientific Officer Mr. Tu Diep M.Sc. (Age 43)Chief Development Officer Key CompetitorsIncannex HealthcareNASDAQ:IXHLProQR TherapeuticsNASDAQ:PRQRCapricor TherapeuticsNASDAQ:CAPRPrelude TherapeuticsNASDAQ:PRLDInventivaNASDAQ:IVAView All Competitors SKYE Stock Analysis - Frequently Asked Questions Should I buy or sell Skye Bioscience stock right now? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Skye Bioscience in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" SKYE shares. View SKYE analyst ratings or view top-rated stocks. What is Skye Bioscience's stock price target for 2024? 2 Wall Street analysts have issued 1-year price targets for Skye Bioscience's shares. Their SKYE share price targets range from $20.00 to $25.00. On average, they expect the company's share price to reach $22.50 in the next year. This suggests a possible upside of 72.8% from the stock's current price. View analysts price targets for SKYE or view top-rated stocks among Wall Street analysts. How have SKYE shares performed in 2024? Skye Bioscience's stock was trading at $2.72 at the start of the year. Since then, SKYE stock has increased by 378.7% and is now trading at $13.02. View the best growth stocks for 2024 here. When is Skye Bioscience's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our SKYE earnings forecast. What ETFs hold Skye Bioscience's stock? ETFs with the largest weight of Skye Bioscience (NASDAQ:SKYE) stock in their portfolio include AdvisorShares Pure Cannabis ETF (YOLO) and Tema Cardiovascular and Metabolics ETF (HRTS). How do I buy shares of Skye Bioscience? Shares of SKYE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:SKYE) was last updated on 5/4/2024 by MarketBeat.com Staff From Our PartnersBiden to Launch “FedNOW” [Move Your Money Now]Priority GoldInvestors Alert: The Next Big Thing in Weight LossBehind the MarketsElon to Transform U.S. Economy? Porter & CompanyAutomatic Income (from home)Awesomely, LLCCould Your Accounts Be Frozen?Allegiance GoldThe asset beating inflation by 4xColonial MetalsStock-Picking AI Predicts #1 Stock of 2024AltimetryThe A.I. story nobody is telling you (Read ASAP)TradeSmith Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Skye Bioscience, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
